Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromomethane SCHEMBL207850 | 0.97 | KMT2A (0.37) | KMT2AMEN1USP2P2RX4ALOX5 | |
| Propanol SCHEMBL27803554 | 0.92 | KMT2A (0.36) | KMT2AMEN1USP2P2RX4ALOX5 | |
| SCHEMBL523372 | 0.84 | ALOX5 (0.39) | KMT2AMEN1USP2P2RX4ALOX5 | |
| Bromomethane SCHEMBL208482 | 0.83 | ALOX5 (0.36) | KMT2AMEN1USP2P2RX4ALOX5 | |
| SCHEMBL10974812 | 0.82 | AKR1B1 (0.43) | KMT2AP2RX4ALOX5AKR1B1THRB | |
| Bromide SCHEMBL27743791 | 0.82 | ALOX5 (0.38) | KMT2AMEN1USP2P2RX4ALOX5 | |
| SCHEMBL4221762 | 0.81 | P2RX4 (0.41) | KMT2AMEN1USP2P2RX4ALOX5 | |
| Bromomethane SCHEMBL15709779 | 0.80 | ALOX5 (0.35) | KMT2AMEN1USP2P2RX4ALOX5 | |
| SCHEMBL4743630 | 0.77 | ALOX5 (0.35) | P2RX4ALOX5AKR1B1THRBTDP1 | |
| SCHEMBL4747072 | 0.77 | ALOX5 (0.35) | P2RX4ALOX5AKR1B1P2RX1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3119766-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| US-20090155185-A1 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC | MEADE CHRISTOPHER JOHN MONTAGUE | 2009-06-18 | — | — | US | disclosed |
| US-7405224-B2 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-07-29 | — | — | US | disclosed |
| CN-101043912-A | Blister pack for an inhaler | BOEHRINGER INGELHEIM INT (DE) | 2007-09-26 | — | — | CN | disclosed |
| EP-1651224-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | Boehringer Ingelheim International GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005013994-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155185-A1 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC | ADRB2, CHRM3, ADRB1 | KMT2A 3602/4885MEN1 2966/4885USP2 1187/4885 |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | KMT2A 4357/4885MEN1 2861/4885USP2 4652/4885 |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | HRH4, HRH3, HRH1 | KMT2A 2183/4885MEN1 2244/4885USP2 4253/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | KMT2A 733/4885MEN1 3116/4885USP2 3140/4885 |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F11, NR3C2 | KMT2A 1763/4885MEN1 345/4885USP2 3410/4885 |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | ADRB2, CHRM3, ADRB1 | KMT2A 3602/4885MEN1 2966/4885USP2 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.